| Line 1: |
Line 1: |
| − | The Hepatitis B vaccine is a recombinant (non-living) vaccine used to prevent infection with the [[Hepatitis B virus]]. Most school age children, health care workers, and others who might be exposed to infectious bodily fluids are recommended or required to become vaccinated.
| + | '''Reverted to version without medical contributor''' |
| | | | |
| | + | The Hepatitis B vaccine, which is required by most states of children in order to be admitted to public school, reportedly increases the risk of multiple sclerosis. Note that Hepatitis B is not contagious in the school setting and is not required of school teachers. It is required of schoolchildren as a result of lobbying by the manufacturer, which makes a profit on every additional shot given. It is lucrative for a company to pass a law that requires people to buy its product! |
| | + | |
| | + | '''Recombinant hepatitis B vaccine and the risk of multiple sclerosis''' |
| | + | <br>A prospective study<ref>http://www.neurology.org/cgi/content/abstract/63/5/838</ref> |
| | + | |
| | + | Miguel A. Hernán, MD, DrPH, Susan S. Jick, DSc, Michael J. Olek, DO and Hershel Jick, MD |
| | + | |
| | + | From the Department of Epidemiology (Dr. Hernán), Harvard School of Public Health, Boston; Boston Collaborative Drug Surveillance Program (Drs. Susan S. Jick and Hershel Jick), Boston University, Lexington, MA; and Department of Neurology (Dr. Olek), College of Medicine, University of California, Irvine. |
| | + | |
| | + | Background: A potential link between the recombinant hepatitis B vaccine and an increased risk of multiple sclerosis (MS) has been evaluated in several studies, but some of them have substantial methodologic limitations. |
| | + | |
| | + | Methods: The authors conducted a nested case-control study within the General Practice Research Database (GPRD) in the United Kingdom. ... |
| | + | |
| | + | Results: The analyses include 163 cases of MS and 1,604 controls. The OR of MS for vaccination within 3 years before the index date compared to no vaccination was 3.1 (95% CI 1.5, 6.3). No increased risk of MS was associated with tetanus and influenza vaccinations. |
| | + | |
| | + | Conclusions: These findings are consistent with the hypothesis that immunization with the recombinant hepatitis B vaccine is associated with an increased risk of MS, and challenge the idea that the relation between hepatitis B vaccination and risk of MS is well understood. |
| | | | |
| | ---- | | ---- |
| | | | |
| | + | '''References:''' <references/> |
| | | | |
| | [[Category:Vaccines]] | | [[Category:Vaccines]] |
| − | [[Category:Medicine]]
| |